These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 39026661)
1. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers. He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S Front Immunol; 2024; 15():1435187. PubMed ID: 39026661 [TBL] [Abstract][Full Text] [Related]
2. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response. Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of single cell and bulk RNA sequencing reveals the heterogeneity of melanoma tumor microenvironment and predicts the response of immunotherapy. Zhang Y; Zhang C; He J; Lai G; Li W; Zeng H; Zhong X; Xie B Inflamm Res; 2024 Aug; 73(8):1393-1409. PubMed ID: 38896289 [TBL] [Abstract][Full Text] [Related]
4. Mapping the single cell spatial immune landscapes of the melanoma microenvironment. Magrill J; Moldoveanu D; Gu J; Lajoie M; Watson IR Clin Exp Metastasis; 2024 Aug; 41(4):301-312. PubMed ID: 38217840 [TBL] [Abstract][Full Text] [Related]
5. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses. Tian J; Quek C Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829 [TBL] [Abstract][Full Text] [Related]
6. Normalization Cancer Immunotherapy for Melanoma. Vesely MD; Chen L J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349 [TBL] [Abstract][Full Text] [Related]
7. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment. Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510 [TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884 [TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer. Yao J; Lin X; Zhang X; Xie M; Ma X; Bao X; Song J; Liang Y; Wang Q; Xue X Hum Vaccin Immunother; 2024 Dec; 20(1):2406063. PubMed ID: 39415535 [TBL] [Abstract][Full Text] [Related]
10. Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma. Wu Z; Zhang R; Bao J; Yin M; Wang X Arch Dermatol Res; 2024 May; 316(6):219. PubMed ID: 38787413 [TBL] [Abstract][Full Text] [Related]
11. Single cell RNA-sequencing in uveal melanoma: advances in heterogeneity, tumor microenvironment and immunotherapy. Tang S; Zhang Y; Huang S; Zhu T; Huang X Front Immunol; 2024; 15():1427348. PubMed ID: 38966635 [TBL] [Abstract][Full Text] [Related]
12. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Coleman S; Xie M; Tarhini AA; Tan AC Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous melanoma and the immunotherapy revolution (Review). Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963 [TBL] [Abstract][Full Text] [Related]
15. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma. Liu D; Yang X; Wu X Front Immunol; 2021; 12():663495. PubMed ID: 34025664 [TBL] [Abstract][Full Text] [Related]
16. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response. Carey AE; Weeraratna AT Pharmacol Ther; 2024 Oct; 262():108698. PubMed ID: 39098769 [TBL] [Abstract][Full Text] [Related]
17. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393 [TBL] [Abstract][Full Text] [Related]
18. Emerging biomarkers for cancer immunotherapy in melanoma. Axelrod ML; Johnson DB; Balko JM Semin Cancer Biol; 2018 Oct; 52(Pt 2):207-215. PubMed ID: 28917578 [TBL] [Abstract][Full Text] [Related]
19. Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies. Wang R; Chen Y; Xie Y; Ma X; Liu Y Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243 [TBL] [Abstract][Full Text] [Related]
20. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. Tian Q; Gao H; Zhao W; Zhou Y; Yang J Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]